title: Mutational Heterogeneity in Melanoma: An Inconvenient Truth.
abstract: Identification of oncogenic BRAF mutations in primary and metastatic melanomas supports a linear model of clonal evolution in cancer. Some mutational studies, however, have failed to identify BRAF mutations in metastatic tumors from patients with BRAFmutant primary melanomas. Using a combination of methods, Riveiro-Falkenbach et al. (2015) assert that technical issues, and not clonal heterogeneity, may explain prior discordant mutational results.
authors.affiliation: The Ronald O. Perelman Department of Dermatology, NYU School of Medicine, NYU Langone Medical Center, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, NYU Langone Medical Center, New York, New York, USA.
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Chang
authors.affiliation: The Ronald O. Perelman Department of Dermatology, NYU School of Medicine, NYU Langone Medical Center, New York, New York, USA; Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, NYU Langone Medical Center, New York, New York, USA. Electronic address: david.polsky@nyumc.org.
authors.forename: David
authors.initials: D
authors.lastname: Polsky
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000235:genetics*; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*
chemical_list: D048493:Proto-Oncogene Proteins B-raf